Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

AC Immune (ACIU) Short-term Investments (2018 - 2025)

AC Immune has reported Short-term Investments over the past 8 years, most recently at $80.8 million for Q4 2025.

  • Quarterly Short-term Investments rose 167.65% to $80.8 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $80.8 million through Dec 2025, up 167.65% year-over-year, with the annual reading at $80.8 million for FY2025, 167.65% up from the prior year.
  • Short-term Investments was $80.8 million for Q4 2025 at AC Immune, down from $100.9 million in the prior quarter.
  • Over five years, Short-term Investments peaked at $125.8 billion in Q4 2021 and troughed at -$119.5 million in Q4 2024.
  • The 5-year median for Short-term Investments is $77.9 million (2025), against an average of $9.9 billion.
  • The largest YoY upside for Short-term Investments was 378997.48% in 2021 against a maximum downside of 417.01% in 2021.
  • A 5-year view of Short-term Investments shows it stood at $125.8 billion in 2021, then crashed by 99.92% to $94.5 million in 2022, then dropped by 20.7% to $74.9 million in 2023, then plummeted by 259.49% to -$119.5 million in 2024, then soared by 167.65% to $80.8 million in 2025.
  • Per Business Quant, the three most recent readings for ACIU's Short-term Investments are $80.8 million (Q4 2025), $100.9 million (Q3 2025), and $122.5 million (Q2 2025).